131 related articles for article (PubMed ID: 16025843)
1. Utilizing a D-amino acid as a drug carrier for antineoplastic nitrogen mustard groups.
Bartzatt RL
Drug Deliv; 2005; 12(3):141-7. PubMed ID: 16025843
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and alkylation activity of a nitrogen mustard agent to penetrate the blood-brain barrier.
Bartzatt RL
Drug Deliv; 2004; 11(1):19-26. PubMed ID: 15168787
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional constructs of aspirin and ibuprofen (non-steroidal anti-inflammatory drugs; NSAIDs) that express antibacterial and alkylation activities.
Bartzatt R; Cirillo SL; Cirillo JD; Donigan L
Biotechnol Appl Biochem; 2003 Jun; 37(Pt 3):273-82. PubMed ID: 12533193
[TBL] [Abstract][Full Text] [Related]
4. Alkylation activity and molecular properties of two antineoplastic agents that utilise indometacin and a conjugate of aspirin with 2-aminonicotinic acid to transport nitrogen mustard groups.
Bartzatt R
Drugs R D; 2007; 8(6):363-72. PubMed ID: 17963427
[TBL] [Abstract][Full Text] [Related]
5. A bifunctional alkylating nitrogen mustard agent that utilizes barbituric acid as carrier drug with the potential for crossing the brain-blood barrier.
Bartzatt R; Donigan L
Recept Channels; 2003; 9(5):309-13. PubMed ID: 14527874
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of aromatic nitrogen mustard agents and analysis of their alkylation activity at physiological pH and temperature.
Bartzatt R; Kasher L
Physiol Chem Phys Med NMR; 2002; 34(2):103-17. PubMed ID: 12841328
[TBL] [Abstract][Full Text] [Related]
7. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
8. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.
Parker LL; Lacy SM; Farrugia LJ; Evans C; Robins DJ; O'Hare CC; Hartley JA; Jaffar M; Stratford IJ
J Med Chem; 2004 Nov; 47(23):5683-9. PubMed ID: 15509167
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Singh RK; Kumar S; Prasad DN; Bhardwaj TR
Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
[TBL] [Abstract][Full Text] [Related]
10. Applying pattern recognition methods to analyze the molecular properties of a homologous series of nitrogen mustard agents.
Bartzatt R; Donigan L
AAPS PharmSciTech; 2006 Apr; 7(2):E35. PubMed ID: 16796353
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of mustard derivatives of thymine.
Hadj-Bouazza A; Teste K; Colombeau L; Chaleix V; Zerrouki R; Kraemer M; Sainte Catherine O
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):439-48. PubMed ID: 18569783
[TBL] [Abstract][Full Text] [Related]
12. Two lead drug designs based on chloramphenicol as the parent structure, which express alkylation activity with potential for clinical applications.
Bartzatt R
J Pharm Pharmacol; 2003 May; 55(5):653-60. PubMed ID: 12831508
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.
Rink SM; Yarema KJ; Solomon MS; Paige LA; Tadayoni-Rebek BM; Essigmann JM; Croy RG
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15063-8. PubMed ID: 8986764
[TBL] [Abstract][Full Text] [Related]
14. Polybenzamide mustards: structure-activity relationships for DNA sequence-specific alkylation.
Turner PR; Ferguson LR; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):61-70. PubMed ID: 10363028
[TBL] [Abstract][Full Text] [Related]
15. Alkylating properties of phosphoramide mustard.
Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
[TBL] [Abstract][Full Text] [Related]
16. Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs.
More GS; Thomas AB; Chitlange SS; Nanda RK; Gajbhiye RL
Anticancer Agents Med Chem; 2019; 19(9):1080-1102. PubMed ID: 30834842
[TBL] [Abstract][Full Text] [Related]
17. New thymine-based derivative of nitrogen mustards.
Boëns B; Teste K; Hadj-Bouazza A; Ismaili J; Zerrouki R
Nucleosides Nucleotides Nucleic Acids; 2012; 31(3):197-205. PubMed ID: 22356235
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and reactivity of aryl nitrogen mustard-oligodeoxyribonucleotide conjugates.
Reed MW; Lukhtanov EA; Gorn V; Kutyavin I; Gall A; Wald A; Meyer RB
Bioconjug Chem; 1998; 9(1):64-71. PubMed ID: 9460548
[TBL] [Abstract][Full Text] [Related]
20. Nitrogen mustard hydrochloride.
Rep Carcinog; 2004; 11():III192-3. PubMed ID: 21105251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
